Summary of landmark brachytherapy trials
| BERT | SCRIPPS | GAMMA– WRIST | BETA-WRIST | PREVENT | GAMMA-ONE | β Irradiation: the Dose-Finding Study Group | |
|---|---|---|---|---|---|---|---|
| PTCA, percutaneous transluminal coronary angioplasty; TLR, target lesion revascularisation; TVR, target vessel revascularisation. | |||||||
| Trial design | Radiation | Radiation v placebo | Radiation v placebo | Radiation | Radiation v placebo | Radiation v placebo | Radiation |
| Type of radiation | β (strontium/ yttrium 90) | γ (iridium 192) | γ (iridium 192) | β ( yttrium-90) | β (phosphorus 32) | γ (iridium 192) | β (yttrium-90) |
| Number of patients | 21 | 55 | 130 | 50 | 105 | 252 | 181 |
| Lesion treated | PTCA sites | Restenosis after PTCA or stenting | In-stent stenosis | In-stent stenosis | De novo or restenosis lesions | In-stent stenosis | Restenosis after PTCA or stenting |
| Restenosis rates (6 months) | 15% | 17% v 54% | 19% v 58% | 22% | 22% v 50% | 32.4% v 55.3% | 15% (for highest dose) |
| TVR at 6 months | 15% | 12% v 45% (TLR) | 26.2% v 67.7% | 34% | 6% v 24% (21% v 32% at 12 months) | 31.3% v 46.3% | 6% (for highest dose) |